東和薬品の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2025/01/21 | 3,120 | 3,130 | 3,040 | 3,055 | -15 | -0.5% | 74,300 |
2025/01/20 | 3,110 | 3,115 | 3,065 | 3,070 | -45 | -1.4% | 92,000 |
2025/01/17 | 3,150 | 3,155 | 3,105 | 3,115 | -35 | -1.1% | 65,500 |
2025/01/16 | 3,220 | 3,220 | 3,135 | 3,150 | -70 | -2.2% | 108,200 |
2025/01/15 | 3,255 | 3,280 | 3,195 | 3,220 | -60 | -1.8% | 99,100 |
2025/01/14 | 3,310 | 3,350 | 3,245 | 3,280 | -20 | -0.6% | 92,800 |
2025/01/10 | 3,330 | 3,390 | 3,300 | 3,300 | -50 | -1.5% | 95,100 |
2025/01/09 | 3,245 | 3,360 | 3,245 | 3,350 | +120 | +3.7% | 158,300 |
2025/01/08 | 3,315 | 3,335 | 3,220 | 3,230 | -90 | -2.7% | 116,600 |
2025/01/07 | 3,320 | 3,335 | 3,275 | 3,320 | ±0 | ±0% | 114,700 |
2025/01/06 | 3,390 | 3,395 | 3,280 | 3,320 | -35 | -1% | 126,300 |
2024/12/30 | 3,350 | 3,365 | 3,300 | 3,355 | +25 | +0.8% | 132,800 |
2024/12/27 | 3,250 | 3,330 | 3,240 | 3,330 | +75 | +2.3% | 146,700 |
2024/12/26 | 3,240 | 3,255 | 3,175 | 3,255 | +5 | +0.2% | 109,500 |
2024/12/25 | 3,245 | 3,285 | 3,190 | 3,250 | +30 | +0.9% | 215,500 |
2024/12/24 | 3,100 | 3,255 | 3,060 | 3,220 | +150 | +4.9% | 259,200 |
2024/12/23 | 2,954 | 3,070 | 2,954 | 3,070 | +155 | +5.3% | 195,100 |
2024/12/20 | 2,821 | 2,939 | 2,820 | 2,915 | +115 | +4.1% | 235,500 |
2024/12/19 | 2,790 | 2,878 | 2,790 | 2,800 | +55 | +2% | 201,800 |
2024/12/18 | 2,783 | 2,800 | 2,740 | 2,745 | -11 | -0.4% | 81,500 |
2024/12/17 | 2,773 | 2,792 | 2,738 | 2,756 | -21 | -0.8% | 83,300 |
2024/12/16 | 2,788 | 2,798 | 2,777 | 2,777 | -11 | -0.4% | 50,600 |
2024/12/13 | 2,773 | 2,829 | 2,771 | 2,788 | -20 | -0.7% | 65,600 |
2024/12/12 | 2,817 | 2,833 | 2,801 | 2,808 | -9 | -0.3% | 47,900 |
2024/12/11 | 2,835 | 2,850 | 2,802 | 2,817 | -15 | -0.5% | 55,200 |
2024/12/10 | 2,856 | 2,857 | 2,823 | 2,832 | +8 | +0.3% | 59,500 |
2024/12/09 | 2,822 | 2,853 | 2,820 | 2,824 | +5 | +0.2% | 79,000 |
2024/12/06 | 2,872 | 2,872 | 2,819 | 2,819 | -40 | -1.4% | 44,300 |
2024/12/05 | 2,882 | 2,906 | 2,835 | 2,859 | -24 | -0.8% | 110,900 |
2024/12/04 | 2,875 | 2,896 | 2,851 | 2,883 | -17 | -0.6% | 80,600 |
2024/12/03 | 2,797 | 2,914 | 2,792 | 2,900 | +103 | +3.7% | 144,500 |
2024/12/02 | 2,802 | 2,815 | 2,781 | 2,797 | -15 | -0.5% | 86,800 |
2024/11/29 | 2,798 | 2,822 | 2,780 | 2,812 | +14 | +0.5% | 91,400 |
2024/11/28 | 2,775 | 2,798 | 2,755 | 2,798 | +28 | +1% | 92,600 |
2024/11/27 | 2,768 | 2,782 | 2,736 | 2,770 | +2 | +0.1% | 120,600 |
2024/11/26 | 2,794 | 2,811 | 2,750 | 2,768 | -32 | -1.1% | 125,000 |
2024/11/25 | 2,841 | 2,856 | 2,800 | 2,800 | -20 | -0.7% | 102,600 |
2024/11/22 | 2,815 | 2,827 | 2,796 | 2,820 | -1 | ±0% | 62,900 |
2024/11/21 | 2,871 | 2,884 | 2,821 | 2,821 | -6 | -0.2% | 84,000 |
2024/11/20 | 2,818 | 2,831 | 2,804 | 2,827 | +9 | +0.3% | 59,600 |
2024/11/19 | 2,858 | 2,873 | 2,807 | 2,818 | -36 | -1.3% | 66,600 |
2024/11/18 | 2,823 | 2,859 | 2,794 | 2,854 | +27 | +1% | 114,300 |
2024/11/15 | 2,900 | 2,909 | 2,827 | 2,827 | -69 | -2.4% | 97,500 |
2024/11/14 | 2,918 | 2,935 | 2,877 | 2,896 | -39 | -1.3% | 143,100 |
2024/11/13 | 3,030 | 3,055 | 2,920 | 2,935 | -165 | -5.3% | 302,000 |
2024/11/12 | 3,085 | 3,170 | 3,085 | 3,100 | +15 | +0.5% | 122,200 |
2024/11/11 | 3,120 | 3,130 | 3,065 | 3,085 | -55 | -1.8% | 86,300 |
2024/11/08 | 3,135 | 3,170 | 3,125 | 3,140 | +20 | +0.6% | 86,900 |
2024/11/07 | 3,120 | 3,145 | 3,090 | 3,120 | ±0 | ±0% | 90,500 |
2024/11/06 | 3,155 | 3,170 | 3,090 | 3,120 | +105 | +3.5% | 216,100 |
51~
100
件表示中 / 6926件
類似銘柄と比較する
現在ご覧いただいている「東和薬品」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
東和薬品 | 253,000円 | +15.0% | -7.3% | 2.77% | 8.30倍 | 0.78倍 |
|
後発医薬品メーカーで国内2強の一角。循環器系に強い。直販軸に発展も卸との取引を拡大中 |
科研薬 | 444,100円 | +22.8% | +113.0% | 4.28% | 12.34倍 | 1.10倍 |
|
旧理研グループの名門。導入の関節機能改善剤、自社創製の爪白癬症薬の2本柱。後発品も展開 |
キッセイ薬 | 371,500円 | +14.5% | -2.3% | 2.42% | 13.59倍 | 0.72倍 |
|
医薬品中堅。泌尿器、腎・透析、未充足医療が重点領域。主軸特許切れ、新しい柱育成。海外は導出 |
鳥居薬 | 435,500円 | +7.1% | -35.0% | 2.76% | 36.01倍 | 1.01倍 |
|
JT傘下。柱の抗HIV薬販売権喪失後、自社製品の腎・透析、アレルゲン等の開発強化 |
ゼリア新薬 | 222,900円 | +14.2% | +41.0% | 2.06% | 10.92倍 | 1.11倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
市場注目の銘柄
チャート関連のコラム